Skip to main content
. Author manuscript; available in PMC: 2017 Aug 6.
Published in final edited form as: PET Clin. 2017 Jul;12(3):269–288. doi: 10.1016/j.cpet.2017.02.001

Fig. 5.

Fig. 5

Whole-body copper-64-DOTA-trastuzumab PET images at 1, 24, and 48 hours after injection (patient 4). (From Tamura K, Kurihara H, Yonemori K, et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med 2013;54(11):1871; with permission.)